


Protecting the value of access to care during and after the COVID-19 pandemic across Europe: focus on antivirals

Dr. Alessandra Medolla
Dr. Vatri Marco


DIFFERENCE BETWEEN INFECTION AND DISEASE

- When a pathogen like a virus enters into the body of a host and multiply or replicate over there, causing harm to the host is called infection. An infection may cause **symptoms** and be **clinically visible** or they may cause **no symptoms and be subclinical**.
- When the condition of the body gets altered from normal and functional state of the organisms to the abnormal and dysfunctional state, associated with certain different kinds of signs and symptoms is called as **disease**.




Simptoms

- Mild simptoms are prevalent in Omicron variant infection
- The hospitalization rate in ICU is lower than the other variants
- Few patients needed oxygen support in comparison with the other variants




- The omicron virus is found in higher concentration in upper respiratory tract cells than lower ones.
- The motivation is the high affinity of the RBD to the ACE receptors of these cells
- It leads with symptoms as:
rhinorrea, congestion, cough,
sore throat, hoarse voice



- The durations of the symptoms is lower in Omicron variant than the others (6,8 days vs 8,9 in Delta variants)
- Among the gastroenterological symptoms, vomiting is the most common one
- Diarrhea and abdominal cramps are common in children aged 5–9 years who are infected with Omicron.
- Gastrointestinal symptoms are present in almost 50% of infected population and in 10-25% persist for months
- These symptoms include heartburn, constipation, diarrhoea and abdominal pain and decline in prevalence with the passage of time.
- The pathophysiology of these symptoms is unknown but likely to be multifactorial

SARS-CoV-2 Affecting Different Parts of Gastrointestinal System



Impact of COVID-19 on the Gastrointestinal Tract: A Clinical Review

Haider Ghazanfar · Sameer Kandhi · Dongmin Shin · Aruna Muthumanickam · Hitesh Gurjar · Zaheer A. Qureshi · Mohammed Shaban · Mohamed Farag · Asim Haider · Pravash Budhathoki · Tanushree Bhatt · Ali Ghezanfer · Abhilesha Jyala · Harish Patel

Increase of Acute cardiovascular event


Prothrombotic effect of the COVID-19

Multifactorial effect of the infection above the cardiovascular system


Critical decrease of follow-up of chronic cardiovascular disease

People concerns about engaging with Hospitals and Health Care System

Admissions for Myocardial Infarction During Covid-19 Pandemic in Italy
Number of Patients admitted in one week



Not only lungs are affected by COVID-19



- Anosmia and ageusia are not peculiar symptoms of Omicron variant infection
- Neurological and cognitive disorders are related to direct and undirect damage of CNS
- Main symptoms are seizure, dizziness and headache


LONG COVID

DEFINITION:


It is defined as the continuation or development of new symptoms 3 months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least 2 months with no other explanation.

NUMBERS AFFECTED:

- Studies show that around 10–20% of people infected by SARS-CoV-2 may go on to develop symptoms that can be diagnosed as long COVID.
- Persistence of symptoms was not related with Covid-19 severity, ICU admission or long hospital stay.



Terminology and Definition of Long COVID



Reported symptoms after SARS-CoV-2 infection



Mental Health

- Anxiety
- Depression
- Sleep problems
- Substance abuse



Respiratory System

- Cough
- Low blood oxygen
- Shortness of breath



Kidney

- Acute kidney injury
- Chronic kidney disease



Gastrointestinal

- Diarrhea
- Acid reflux
- Constipation




Skin Disorders

- Rash
- Hair loss



Blood Disorders

- Anemia
- Blood clots



Nervous System

- Stroke
- Headaches
- Memory problems
- Loss of smell and taste



Cardiovascular

- Arrhythmia
- Palpitations
- Heart failure
- Acute coronary disease



Metabolic/Endocrine

- Obesity
- Diabetes
- High cholesterol



Musculoskeletal


- Joint pain
- Muscle weakness



General


- Fatigue
- Malaise
- Mitochondrial dysfunction

Immune dysregulation




Immune dysregulation, with or without reactivation of underlying pathogens, including herpesviruses such as EBV and HHV-6

Microbiota dysbiosis



Impacts of SARS-CoV-2 on the microbiota and virome (including SARS-CoV-2 persistence)

Autoimmunity and immune priming




Autoimmunity and primed immune cells from molecular mimicry

Blood clotting and endothelial abnormalities





Microvascular blood clotting with endothelial dysfunction

Dysfunctional neurological signalling



Dysfunctional signalling in the brainstem and/or vagus nerve



How can I prevent long COVID?

- The best way to avoid long COVID, is to avoid getting COVID in the first place, like from vaccination and masking.
- There is also evidence that vaccinated people who get COVID-19 are less likely to have post-COVID conditions.

What are the treatment options?

- There is no specific cure for long COVID, but there may be treatments that can help you feel better depending in your systoms.
- In many hospitals they build a team of health professionals to help people with long covid.



AUTHORISED DRUGS FOR COVID-19 IN EU

Paxlovid

Remdesivir

Monlupinavir

Anakinra

Tocilizumab

Regdamvimab


Sotrovimab

Casilinimab/Imdevimab

Tixagevimab/tilgavimad




1 Attachment and entry




**Anti-spike
monoclonal
antibodies**

**2 Translation of
viral proteins**



3 Proteolysis




**Protease inhibitor:
Nirmatrelvir/ritona
vir (Paxlovid)**

4 RNA replication

Replication
transcription complex

Circulating RNA




Molnupiravir (Lagevrio) - Remdesivir (Veklury)


**5 Transcription and
translation of structural
and accessory proteins**



**6 Assembly, packaging,
and release**



ANTI-SPIKE MONOCLONAL ANTIBODIES



Used in patients at increased risk of their COVID-19 disease becoming severe and who do not require supplemental oxygen.

Some monoclonal antibodies are also approved for preventing COVID-19.

Monoclonal antibodies attach to the spike proteins and prevent the virus entering others cells

Poorly effective at neutralizing most Omicron variants and do not significantly neutralise the variants which are dominant in the EU

ANTIVIRALS



Based on the totality of data, it was not possible to conclude that Lagevrio can reduce the risk of hospitalisation or death or shorten the duration of illness or time to recovery in adults at risk of severe disease. Furthermore, it was not possible to identify a specific group of patients in whom a clinically relevant benefit of Lagevrio could be demonstrated.

Antivirals are a class of drug that inhibit viral replication


	PAXLOVID®	RENDESIVIR	MOLNUPINAVIR
Pros	<ul style="list-style-type: none"> • Highly efficacious • Oral regimen • Ritonavir studied (safe) in pregnancy 	<ul style="list-style-type: none"> • Highly efficacious • Studied in pregnancy • Few/no drug interactions 	<ul style="list-style-type: none"> • Oral regimen • Not recommended in pregnancy • No known drug interactions
Cons	<ul style="list-style-type: none"> • Drug drug interactions 	<ul style="list-style-type: none"> • Requires IV infusion on 3 consecutive days 	<ul style="list-style-type: none"> • Low efficacy • Concern: mutagenicity • Not recommended in pregnancy/children





IMMUNOMODULATORS

- **Anakinra** is a monoclonal antibody that blocks the interleukin IL-1. Guidelines in January 2023 found insufficient evidence to recommend for or against anakinra for the treatment of COVID-19.
- **Tocilizumab** is an IL-6 receptor monoclonal antibody. Guidelines conditionally suggest the use of tocilizumab among hospitalized patients with progressive severe or critical COVID-19.



COTICOSTEROIDS

Can be use in SARS-CoV-2 infection among hospitalized patients with severe COVID-19 (defined as patients with SpO2 \leq 94% on room air, or those who require either supplemental oxygen, mechanical ventilation or extracorporeal mechanical oxygenation)



HYDROXYCHLOROQUINE/CHLOROQUINE

- Data from *in vitro* experimental studies show that hydroxychloroquine and chloroquine have inhibitory effects on SARS-CoV-2.
- RCTs did not demonstrate a benefit of hydroxychloroquine for the treatment of COVID-19 compared to the hydroxychloroquine arm.

AZITHROMYCIN

The antibiotic azithromycin has been postulated for its antiviral and anti-inflammatory benefits and has been studied for the treatment of COVID-19. However, multiple studies have not identified any clinical benefit.



COVALESCENT PLASMA

- Covalent plasma is the a... antibody... recovery... can be... subsequent... beneficial effects... covalent plasma, no difference... observed in mortality or other clinical outcomes between the plasma and placebo groups.



An estimated 100 million Cancer screening tests were not performed in Europe as a result of the pandemic



European
cancer
ORGANISATION

Colon-rectal cancer

- Occult blood in the stool


Breast cancer

- Mammography

Cervical cancer

- Pap-test

- Reduced screenings and testing can be attributed to both health system issues and patient concerns
- Re-prioritisation of health system resources has caused a reduction in capacity and significant disruption to the provision of health services
- Patient attitudes and concerns about engaging with the health system, especially **for asymptomatic conditions** and **preventative measures**, have also triggered the steep decline in screenings and testing



At the beginning of the COVID-19 pandemic, a suspension of many nonurgent medical services was imposed all over the world.

Affected services concerned, for example, family planning and abortion⁴; HIV prevention, testing, and care, and cancer prevention

On April 2020 we registered the lowest peak of cancer screenings provided with a reduction near to 70% in comparison with the previous period

The average of lost screening is 45%

It suppose to be the cause of a raise of cancer mortality for delayed diagnosis and therapies

Analisis conducted on data from North and South America, Europe on January to October 2020






Figure 2.18: New HIV diagnoses, by transmission mode and year of diagnosis, West, 2011–2020




Data from Andorra, Monaco and Portugal excluded due to inconsistent reporting during the period; data from Iceland, Ireland and Malta excluded due to incomplete reporting on transmission mode during the period; data from Italy and Spain excluded due to increasing coverage of national surveillance during the period.

Figure 2.16: New HIV diagnoses, by transmission mode and year of diagnosis, Centre, 2011–2020




Data from Bosnia and Herzegovina, North Macedonia, Poland and Turkey excluded due to incomplete reporting on transmission mode during the period.

Arithmetic scale



The number of **new HIV infection** diagnosis on average has been reduced from 2020 all over European countries. Because of the health care system measure adopted to face the COVID-19 pandemia the number of test provided has been strictly reduced



Selected examples of actions by country

Based on interviews and literature review



Estonia – Making use of online medical records with patients having access to their own records



Italy – Effective triaging of overdue breast cancer screening to prioritise those most at risk



France – Patient hotline established to answer questions from patients and their loved ones



Netherlands – Major focus on public communication and campaigns



Germany – National organisations form 'task force' to spread consistent messaging around visiting the doctor with symptoms



Portugal – Breast screening mobile units with guaranteed safety conditions after each screening



Greece – Virtual networking between multi-disciplinary teams



UK – Making use of additional capacity in private sector hospitals

- Ghazanfar H, Kandhi S, Shin D, et al. (March 20, 2022) Impact of COVID-19 on the Gastrointestinal Tract: A Clinical Review. Cureus 14(3): e23333. doi:10.7759/cureus.23333
- **The nervous system during COVID-19: Caught in the crossfire** Nick R. Natale, John R. Lukens, William A. Petri Jr First published: 30 June 2022
- IQVIA institute- Cancer won't wait- 2021
- **Global Association of COVID-19 Pandemic Measures With Cancer Screening** A Systematic Review and Meta-analysis
 - 2020 Jun 7;41(22):2083-2088.
doi: 10.1093/eurheartj/ehaa409.**Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era**